230,400 Shares in Ralliant Corporation $RAL Purchased by Bank of Nova Scotia

Key Points

• Bank of Nova Scotia acquired 230,400 Ralliant shares during the second quarter, worth approximately $16.96 million and representing about 0.21% of the company.
• Ralliant insiders sold shares under pre-arranged Rule 10b5-1 plans, including 6,062 shares sold by SVP Karen Bick and 12,936 shares sold by CEO Tamara Newcombe.
• Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $75.70 price target. Ralliant also exceeded quarterly EPS estimates and declared a $0.05 quarterly dividend.

Bank of Nova Scotia bought a new stake in Ralliant Corporation (NYSE:RAL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 230,400 shares of the company's stock, valued at approximately $16,964,000. Bank of Nova Scotia owned about 0.21% of Ralliant at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Danske Bank A S acquired a new position in shares of Ralliant in the 4th quarter worth approximately $25,000. Dunhill Financial LLC purchased a new position in shares of Ralliant during the 2nd quarter worth approximately $25,000. Allworth Financial LP boosted its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company's stock worth $26,000 after purchasing an additional 293 shares during the period. Palisade Asset Management LLC acquired a new stake in Ralliant in the 3rd quarter valued at approximately $26,000. Finally, BOKF NA acquired a new stake in Ralliant in the 3rd quarter valued at approximately $29,000.

Insider Buying and Selling at Ralliant

In related news, SVP Karen M. Bick sold 6,062 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares of the company's stock, valued at $2,280,096. The trade was a 16.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the company's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. This trade represents a 4.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on RAL shares. TD Cowen upped their price target on Ralliant from $70.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Oppenheimer lifted their price objective on Ralliant from $50.00 to $65.00 and gave the company an "outperform" rating in a research note on Wednesday, May 13th. Evercore initiated coverage on Ralliant in a report on Tuesday, June 9th. They issued an "outperform" rating and a $80.00 price objective on the stock. Wall Street Zen raised Ralliant from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Royal Bank Of Canada increased their target price on Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $75.70.

Ralliant Price Performance

Shares of RAL opened at $63.72 on Monday. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The firm's 50 day moving average price is $68.94 and its 200 day moving average price is $55.94. The company has a market cap of $7.05 billion, a P/E ratio of -5.87, a PEG ratio of 2.36 and a beta of 1.61. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75.

Ralliant (NYSE:RAL - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, research analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant's dividend payout ratio (DPR) is presently -1.84%.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source